首页> 外文OA文献 >Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis
【2h】

Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis

机译:Globo H和SSEA3在乳腺癌干细胞中的表达以及岩藻糖基转移酶1和2在Globo H合成中的参与

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We examined the expression in breast cancer stem cells (BCSCs) of Globo H, a potential tumor-associated antigen for immunotherapy of epithelial cancers including breast cancer. Flow cytometry revealed Globo H expression in 25/41 breast cancer specimens (61.0%). Non-BCSCs from 25/25 and BCSCs from 8/40 (20%) expressed Globo H. We showed the expression of stage-specific embryonic antigen 3 (SSEA3), the pentasaccharide precursor of Globo H, in 31/40 (77.5%) tumors. Non-BCSCs from 29/31 and BCSCs from 25/40 (62.5%) expressed SSEA3. Like Globo H, SSEA3 expression in normal tissues was predominately at the secretory borders of epithelium, where access to the immune system is restricted. Immunization of mice with Globo H-KLH and α-GalCer induced antibodies reactive with Globo H and SSEA3, suggesting that a Globo H-based vaccine will target tumor cells expressing Globo H or SSEA3. We next sought to reduce Globo H expression by siRNA targeting fucosyltransferase (FUT) 1 and 2, which mediate alpha-1,2 linkage of fucose to SSEA3 to generate Globo H. We showed both genes to be involved in the biosynthesis of Globo H. Moreover, FUT2 expression in BCSCs was significantly lower than in non-BCSCs harvested from a primary human breast cancer in NOD/SCID mouse, whereas FUT1 was slightly lower in BCSCs. Thus, the lower expression of Globo H in BCSCs may be attributed to less FUT2/FUT1, and to reduced SSEA3 in BCSCs compared with non-BCSCs. Our findings provide insight into further development of a Globo H-based vaccine and FUT1/FUT2-targeted therapy for breast cancer.
机译:我们检查了Globo H在乳腺癌干细胞(BCSC)中的表达,Globo H是一种潜在的与肿瘤相关的抗原,用于上皮癌(包括乳腺癌)的免疫治疗。流式细胞仪显示在25/41个乳腺癌标本中Globo H表达(61.0%)。来自25/25的非BCSC和来自8/40的BCSC(20%)表达GloboH。我们在31/40(77.5%)中显示了Globo H的五糖前体阶段特异性胚胎抗原3(SSEA3)的表达。 )肿瘤。来自29/31的非BCSC和来自25/40的BCSC(62.5%)表示SSEA3。像Globo H一样,SSEA3在正常组织中的表达主要在上皮的分泌边界处,那里限制了免疫系统的访问。用Globo H-KLH和α-GalCer诱导的与Globo H和SSEA3反应的抗体对小鼠进行免疫接种,表明基于Globo H的疫苗将靶向表达Globo H或SSEA3的肿瘤细胞。接下来,我们试图通过靶向岩藻糖基转移酶(FUT)1和2的siRNA来降低Globo H的表达,该介导的岩藻糖与SSEA3的α-1,2键合产生了Globo H.我们证明了这两个基因都与Globo H的生物合成有关。此外,在NOD / SCID小鼠中,BCSC中FUT2的表达明显低于从原发性人类乳腺癌中收获的非BCSC,而BCSC中的FUT1则略低。因此,与非BCSC相比,BCSC中Globo H的较低表达可能归因于较少的FUT2 / FUT1,以及由于BCSC中SSEA3减少。我们的发现为进一步开发基于Globo H的疫苗和针对FUT1 / FUT2的乳腺癌疗法提供了见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号